99mTc-MIRC208 SPECT/CT Imaging for HER2-Positive Cancer Patients

Summary

This is an open-labeled Single-Photon Emission Computed Tomography/Computed Tomography(SPECT/CT) study to investigate the clinical value of 99mTc-MIRC208 in HER2 status measurement of cancer patients. A single dose of 14.8 MBq/kg body weight will be injected intravenously. The whole-body SPECT/CT examination will be performed 2 h post-injection and the visual and semiquantitative methods will be used to assess the SPECT/CT images.

Timeline

Start

2020-09-01

Primary completion

2024-08-30

Completion

2024-08-30

Drugs

Indications